Wedbush Securities’s aTyr Pharma ATYR Stock Holding History

Wedbush Securities’s Portfolio ATYR Stock Details ATYR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-4,805	Closed	-$25K	–	1029
2019 Q2	$25K	Buy	4,805 +2,948	+159%	+$20K	﹤0.01%	970
2019 Q1	$14K	Buy	+1,857	New	+$13.2K	﹤0.01%	917
2018 Q3	–	Sell	-1,679	Closed	-$21K	–	945
2018 Q2	$21K	Buy	+1,679	New	+$39.8K	﹤0.01%	865
2017 Q1	–	Sell	-1,000	Closed	-$30K	–	888
2016 Q4	$30K	Buy	+1,000	New	+$41K	﹤0.01%	796
2016 Q3	–	Sell	-893	Closed	-$35K	–	871
2016 Q2	$35K	Buy	+893	New	+$41.5K	0.01%	749

Other funds holding ATYR

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PVMCV

Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

GHCM

Glen Harbor Capital Management San Diego, California $4.82B AUM 4.69% 1-Year Est. Return

MCIM

Meadow Creek Investment Management Atlanta, Georgia $5.09B AUM 5.82% 1-Year Est. Return

Wedbush Securities's ATYR Position: Q3 2019 in Review

Wedbush Securities sold out of aTyr Pharma (ATYR) in Q3 2019, closing a stake of 4,805 shares — an estimated $25K sold.

Wedbush Securities first reported a position in ATYR in Q2 2016 and held it in 5 quarters. The position peaked at $35K in Q2 2016. 19 funds tracked by Wall St. Rank hold ATYR as of Q3 2019.

Wedbush Securities reported no remaining aTyr Pharma position as of Q3 2019 after selling out during the quarter.
Wedbush Securities sold 4,805 aTyr Pharma shares in Q3 2019, an estimated $25K.
Wedbush Securities first reported a position in aTyr Pharma in Q2 2016 and held it in 5 quarters.
Wedbush Securities's aTyr Pharma position peaked at $35K in Q2 2016.
19 funds tracked by Wall St. Rank held aTyr Pharma as of Q3 2019.

Based on Wedbush Securities's 13F filing for Q3 2019, filed 17 Oct 2019.